Intelligence · Patents
Patents expiring in 2045
Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.
- Patents
- 1,566
Quick answer
1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12398197
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
granted -
US 12398212
Methods for treating or preventing asthma by administering an IL-4R antagonist
granted -
US 12398373
Enhanced immune effector cells and use thereof
granted -
US 12398379
Compositions and methods for treating ornithine transcarbamylase deficiency
granted -
US 12396444
Mouse comprising a humanized TRKB locus
granted -
US 12398087
Methods of making bempedoic acid and compositions of the same
granted -
US 12398375
Methods for improved poxvirus yields
granted -
US 12397013
Extrahepatic delivery
granted -
US 12397058
Metabolically stable prodrugs
granted -
US 12397062
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12397034
Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons
granted -
US 12398131
Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof
granted -
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12396952
Tuning of release kinetics in hydrogels
granted -
US 12396991
Biomarkers for the diagnosis and treatment of fibrotic lung disease
granted -
US 12396989
Nicorandil derivatives
granted -
US 12396988
Methods of using muscarinic antagonists in the treatment of depression
granted -
US 12404313
GDNF fusion polypeptides and methods of use thereof
granted -
US 12404533
Bioconjugate vaccines' synthesis in prokaryotic cell lysates
granted -
US 12404505
Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12403164
Lentiviral vector formulations
granted -
US 12403141
Deuterated MK2 pathway inhibitors and methods of using the same
granted -
US 12403093
Methods for production of MSC-derived exosomes
granted -
US 12404328
Multi-specific binding proteins and methods of use thereof
granted -
US 12404497
Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
granted -
US 12404227
Methods of making bempedoic acid and compositions of the same
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12403087
Topical antiviral compositions, delivery systems, and methods of using the same
granted -
US 12404337
Compositions, doses, and methods for treatment of thyroid eye disease
granted -
US 12404315
Protease-activating CD45-gate CAR
granted -
US 12403202
Dosage of claudin-6 conjugates for cancer treatment
granted -
US 12403090
Oral film compositions and dosage forms having precise active dissolution profiles
granted -
US 12404347
Glucuronoxylomannan (GXM) receptor chimeric antigen receptors and use thereof
granted -
US 12404297
Salts and crystal forms of GABA-A positive allosteric modulator
granted -
US 12403137
Compounds and methods of use
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12403167
Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament
granted -
US 12403200
Methods and compositions for treating autoimmune diseases
granted -
US 12403196
Ras inhibitors
granted -
US 12403134
Method for improving or enhancing cognition
granted -
US 12403203
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 12404508
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
granted -
US 12403192
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12404243
Inhibitors of the Wnt/beta-catenin pathway
granted
Frequently asked questions
How many pharma patents expire in 2045?
1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.